FORBES-TATE for GENENTECH
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Issues related to Intellectual Property and Process Patent Issues - HR 1908, Patent Reform Act (all provisions); Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues re: comparative effectiveness and followon biologics; FDA repeal of Avastin; coverage of Lucentis & Avastin; trade issues; & HR 942- American Research & Competiveness Act of 2011.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY FORBES New | Staff Director, Senate Finance Committee ; ; Chief of Staff, Senator Max Baucus ; ; Deputy Asst, Special Asst, Deputy Director EOP |
| ELIZABETH GREER New | Chief of Staff, Rep. Allen Boyd |
Medicare/Medicaid MMM
Issues related to Intellectual Property and Process Patent Issues - HR 1908, Patent Reform Act (all provisions); Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues re: comparative effectiveness and followon biologics; FDA repeal of Avastin; coverage of Lucentis & Avastin; trade issues; & HR 942- American Research & Competiveness Act of 2011.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY FORBES New | Staff Director, Senate Finance Committee ; ; Chief of Staff, Senator Max Baucus ; ; Deputy Asst, Special Asst, Deputy Director EOP |
| ELIZABETH GREER New | Chief of Staff, Rep. Allen Boyd |
Trade (domestic/foreign) TRD
Issues related to Intellectual Property and Process Patent Issues - HR 1908, Patent Reform Act (all provisions); Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues re: comparative effectiveness and followon biologics; FDA repeal of Avastin; coverage of Lucentis & Avastin; trade issues; & HR 942- American Research & Competiveness Act of 2011.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY FORBES New | Staff Director, Senate Finance Committee ; ; Chief of Staff, Senator Max Baucus ; ; Deputy Asst, Special Asst, Deputy Director EOP |
| ELIZABETH GREER New | Chief of Staff, Rep. Allen Boyd |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| F. HOFFMANN-LA ROCHE LTD. | Switzerland | Switzerland | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.